Directional Atherectomy and Anti- Restenotic Therapy in ......Carlos Abel Gutierrez Diaz I have the...
Transcript of Directional Atherectomy and Anti- Restenotic Therapy in ......Carlos Abel Gutierrez Diaz I have the...
![Page 1: Directional Atherectomy and Anti- Restenotic Therapy in ......Carlos Abel Gutierrez Diaz I have the following potential conflicts of interest to report: X Consulting: Medtronic, Bard,](https://reader030.fdocuments.us/reader030/viewer/2022040803/5e3e6f4c9f9d867e060a74d5/html5/thumbnails/1.jpg)
Directional Atherectomy and Anti-Restenotic Therapy in Multilevel Disease
Carlos Abel Gutierrez Diaz MD Mexico City
Angeles Mocel Hospital
![Page 2: Directional Atherectomy and Anti- Restenotic Therapy in ......Carlos Abel Gutierrez Diaz I have the following potential conflicts of interest to report: X Consulting: Medtronic, Bard,](https://reader030.fdocuments.us/reader030/viewer/2022040803/5e3e6f4c9f9d867e060a74d5/html5/thumbnails/2.jpg)
Disclosure
Speaker name:Carlos Abel Gutierrez DiazI have the following potential conflicts of interest to report: X Consulting: Medtronic, Bard, Abbott, Boston Scientific Employment in industry Stockholder of a healthcare company Owner of a healthcare company Other(s)
I do not have any potential conflict of interest
![Page 3: Directional Atherectomy and Anti- Restenotic Therapy in ......Carlos Abel Gutierrez Diaz I have the following potential conflicts of interest to report: X Consulting: Medtronic, Bard,](https://reader030.fdocuments.us/reader030/viewer/2022040803/5e3e6f4c9f9d867e060a74d5/html5/thumbnails/3.jpg)
Predictors of poor outcome.
• Location: Iliac > Femoropopliteal > Tibial.
• Stenosis vs Occlusion.
• Length: Short vs Long.
• Calcium.
• Runoff status.
• Multifocal.
• Multilevel. Critical limb ischemia
![Page 4: Directional Atherectomy and Anti- Restenotic Therapy in ......Carlos Abel Gutierrez Diaz I have the following potential conflicts of interest to report: X Consulting: Medtronic, Bard,](https://reader030.fdocuments.us/reader030/viewer/2022040803/5e3e6f4c9f9d867e060a74d5/html5/thumbnails/4.jpg)
Primary patency: 78.9% vs 50.1%
CD - TLR: 9.1% vs 28.3%
Laird J, Schneider P, Tepe G, et al. Durability of Treatment Effect Using a Drug-Coated Balloon for Femoropopliteal Lesions. J Am Coll Cardiol 2015;66:2329-2338.
• Sustained benefit of DCB over PTA. • Benefit in longer and complex lesions (CTO’s),
diabetic and females. • Less reinterventions.
![Page 5: Directional Atherectomy and Anti- Restenotic Therapy in ......Carlos Abel Gutierrez Diaz I have the following potential conflicts of interest to report: X Consulting: Medtronic, Bard,](https://reader030.fdocuments.us/reader030/viewer/2022040803/5e3e6f4c9f9d867e060a74d5/html5/thumbnails/5.jpg)
![Page 6: Directional Atherectomy and Anti- Restenotic Therapy in ......Carlos Abel Gutierrez Diaz I have the following potential conflicts of interest to report: X Consulting: Medtronic, Bard,](https://reader030.fdocuments.us/reader030/viewer/2022040803/5e3e6f4c9f9d867e060a74d5/html5/thumbnails/6.jpg)
What about complex lesions?
Long, calcified, CTO’s, diabetic, multilevel. Real world cases.
![Page 7: Directional Atherectomy and Anti- Restenotic Therapy in ......Carlos Abel Gutierrez Diaz I have the following potential conflicts of interest to report: X Consulting: Medtronic, Bard,](https://reader030.fdocuments.us/reader030/viewer/2022040803/5e3e6f4c9f9d867e060a74d5/html5/thumbnails/7.jpg)
Fanelli F, Cannavale A, Boatta E, et al. Lower Limb Multilevel treatment with Drug/Eluting Balloons: 6-Month Results from the DEBELLUM Randomized Trial. J Endovasc Ther 2012;19:571-580.
• Late lumen loss lower in DCB: 0.5 vs 1.6 mm.
• TLR: 6.1% vs 23.6%.
• Higher late lumen loss in calcified lesions: barrier
to drug absortion.
• Small sample size: not support real conclusions.
![Page 8: Directional Atherectomy and Anti- Restenotic Therapy in ......Carlos Abel Gutierrez Diaz I have the following potential conflicts of interest to report: X Consulting: Medtronic, Bard,](https://reader030.fdocuments.us/reader030/viewer/2022040803/5e3e6f4c9f9d867e060a74d5/html5/thumbnails/8.jpg)
Stavroulakis K, Bisdas T, Torsello G, et al. Combined Directional Atherectomy and Drug-Eluting Balloon Angioplasty for Isolated Popliteal Artery Lesions in Patients with Peripheral Artery Disease J Endovasc Ther 2015;22:847-852.
• 21 patients with isolated popliteal lesions.
• Primary patency at 12 and 18 months: 95% and 90%.
• Better penetration of antiproliferative drug.
![Page 9: Directional Atherectomy and Anti- Restenotic Therapy in ......Carlos Abel Gutierrez Diaz I have the following potential conflicts of interest to report: X Consulting: Medtronic, Bard,](https://reader030.fdocuments.us/reader030/viewer/2022040803/5e3e6f4c9f9d867e060a74d5/html5/thumbnails/9.jpg)
![Page 10: Directional Atherectomy and Anti- Restenotic Therapy in ......Carlos Abel Gutierrez Diaz I have the following potential conflicts of interest to report: X Consulting: Medtronic, Bard,](https://reader030.fdocuments.us/reader030/viewer/2022040803/5e3e6f4c9f9d867e060a74d5/html5/thumbnails/10.jpg)
• 59 year-old woman. • Smoker, diabetic. • Ischemic rest pain and tissue loss. • Left CFA anterograde access.
![Page 11: Directional Atherectomy and Anti- Restenotic Therapy in ......Carlos Abel Gutierrez Diaz I have the following potential conflicts of interest to report: X Consulting: Medtronic, Bard,](https://reader030.fdocuments.us/reader030/viewer/2022040803/5e3e6f4c9f9d867e060a74d5/html5/thumbnails/11.jpg)
• CTO Cap analysis: antegrade congruos concavity.
• Hibernating lumen. • Successful crossing: support catheter. • Predilatation: < 1 mm than the vessel
reference diameter. • TurboHawk directional atherectomy
with distal embolic protection filter. • BTK PTA. • Femoropopliteal DCB.
![Page 12: Directional Atherectomy and Anti- Restenotic Therapy in ......Carlos Abel Gutierrez Diaz I have the following potential conflicts of interest to report: X Consulting: Medtronic, Bard,](https://reader030.fdocuments.us/reader030/viewer/2022040803/5e3e6f4c9f9d867e060a74d5/html5/thumbnails/12.jpg)
![Page 13: Directional Atherectomy and Anti- Restenotic Therapy in ......Carlos Abel Gutierrez Diaz I have the following potential conflicts of interest to report: X Consulting: Medtronic, Bard,](https://reader030.fdocuments.us/reader030/viewer/2022040803/5e3e6f4c9f9d867e060a74d5/html5/thumbnails/13.jpg)
![Page 14: Directional Atherectomy and Anti- Restenotic Therapy in ......Carlos Abel Gutierrez Diaz I have the following potential conflicts of interest to report: X Consulting: Medtronic, Bard,](https://reader030.fdocuments.us/reader030/viewer/2022040803/5e3e6f4c9f9d867e060a74d5/html5/thumbnails/14.jpg)
Fanelli F, Cannavale A, Gazzetti M, et al. Calcium Burden Assessment and Impact on Drug-Eluting Balloons in Peripheral Arterial Disease. Cardiovasc Interven Radiol 2014;37:898-907.
DCB efficacy can be affected by calcium (circumferential distribution)
Debulking
![Page 15: Directional Atherectomy and Anti- Restenotic Therapy in ......Carlos Abel Gutierrez Diaz I have the following potential conflicts of interest to report: X Consulting: Medtronic, Bard,](https://reader030.fdocuments.us/reader030/viewer/2022040803/5e3e6f4c9f9d867e060a74d5/html5/thumbnails/15.jpg)
• 54 year-old man. • Smoker and diabetic. • Ischemic rest pain and tissue loss. • Left CFA anterograde access. • Femoropopliteal and tibial vessel disease.
![Page 16: Directional Atherectomy and Anti- Restenotic Therapy in ......Carlos Abel Gutierrez Diaz I have the following potential conflicts of interest to report: X Consulting: Medtronic, Bard,](https://reader030.fdocuments.us/reader030/viewer/2022040803/5e3e6f4c9f9d867e060a74d5/html5/thumbnails/16.jpg)
• Severe calcification. • Successful crossing: support catheter. • 0.014 Guidewire: PTA - MPA - PA - ATA. • Predilatation: < 1 mm than the vessel
reference diameter.
![Page 17: Directional Atherectomy and Anti- Restenotic Therapy in ......Carlos Abel Gutierrez Diaz I have the following potential conflicts of interest to report: X Consulting: Medtronic, Bard,](https://reader030.fdocuments.us/reader030/viewer/2022040803/5e3e6f4c9f9d867e060a74d5/html5/thumbnails/17.jpg)
• TurboHawk directional atherectomy with distal embolic protection filter.
• BTK DCB. • Femoropopliteal DCB.
![Page 18: Directional Atherectomy and Anti- Restenotic Therapy in ......Carlos Abel Gutierrez Diaz I have the following potential conflicts of interest to report: X Consulting: Medtronic, Bard,](https://reader030.fdocuments.us/reader030/viewer/2022040803/5e3e6f4c9f9d867e060a74d5/html5/thumbnails/18.jpg)
![Page 19: Directional Atherectomy and Anti- Restenotic Therapy in ......Carlos Abel Gutierrez Diaz I have the following potential conflicts of interest to report: X Consulting: Medtronic, Bard,](https://reader030.fdocuments.us/reader030/viewer/2022040803/5e3e6f4c9f9d867e060a74d5/html5/thumbnails/19.jpg)
![Page 20: Directional Atherectomy and Anti- Restenotic Therapy in ......Carlos Abel Gutierrez Diaz I have the following potential conflicts of interest to report: X Consulting: Medtronic, Bard,](https://reader030.fdocuments.us/reader030/viewer/2022040803/5e3e6f4c9f9d867e060a74d5/html5/thumbnails/20.jpg)
Zeller T, Langhoff R, Rocha-Singh K, et al. Directional Atherectomy Followed by a Paclitaxel-Coated Balloon to Inhibit Restenosis and Maintain Vessel Patency. Twelve-Month Results of the DEFINITIVE AR Study. Circ Cardiovasc Interv 2017;.
• 102 patients: 48 (DA + DCB) and 54 (DCB).
• Mean lesion length: 106 mm.
• Primary patency at 1 year: 82.4% (DA + DCB), 71.8%
(DCB).
• Potential advantage in long > 10 cm and severely
calcified lesions.
![Page 21: Directional Atherectomy and Anti- Restenotic Therapy in ......Carlos Abel Gutierrez Diaz I have the following potential conflicts of interest to report: X Consulting: Medtronic, Bard,](https://reader030.fdocuments.us/reader030/viewer/2022040803/5e3e6f4c9f9d867e060a74d5/html5/thumbnails/21.jpg)
Increasing complexity of lesions
PTA Bare metal stent
Atherectomy DCB DES
More endovascular tools are needed: technique and devices
![Page 22: Directional Atherectomy and Anti- Restenotic Therapy in ......Carlos Abel Gutierrez Diaz I have the following potential conflicts of interest to report: X Consulting: Medtronic, Bard,](https://reader030.fdocuments.us/reader030/viewer/2022040803/5e3e6f4c9f9d867e060a74d5/html5/thumbnails/22.jpg)
![Page 23: Directional Atherectomy and Anti- Restenotic Therapy in ......Carlos Abel Gutierrez Diaz I have the following potential conflicts of interest to report: X Consulting: Medtronic, Bard,](https://reader030.fdocuments.us/reader030/viewer/2022040803/5e3e6f4c9f9d867e060a74d5/html5/thumbnails/23.jpg)
![Page 24: Directional Atherectomy and Anti- Restenotic Therapy in ......Carlos Abel Gutierrez Diaz I have the following potential conflicts of interest to report: X Consulting: Medtronic, Bard,](https://reader030.fdocuments.us/reader030/viewer/2022040803/5e3e6f4c9f9d867e060a74d5/html5/thumbnails/24.jpg)
![Page 25: Directional Atherectomy and Anti- Restenotic Therapy in ......Carlos Abel Gutierrez Diaz I have the following potential conflicts of interest to report: X Consulting: Medtronic, Bard,](https://reader030.fdocuments.us/reader030/viewer/2022040803/5e3e6f4c9f9d867e060a74d5/html5/thumbnails/25.jpg)
![Page 26: Directional Atherectomy and Anti- Restenotic Therapy in ......Carlos Abel Gutierrez Diaz I have the following potential conflicts of interest to report: X Consulting: Medtronic, Bard,](https://reader030.fdocuments.us/reader030/viewer/2022040803/5e3e6f4c9f9d867e060a74d5/html5/thumbnails/26.jpg)
![Page 27: Directional Atherectomy and Anti- Restenotic Therapy in ......Carlos Abel Gutierrez Diaz I have the following potential conflicts of interest to report: X Consulting: Medtronic, Bard,](https://reader030.fdocuments.us/reader030/viewer/2022040803/5e3e6f4c9f9d867e060a74d5/html5/thumbnails/27.jpg)
N = 14
Age 68,3
Men 71,4%
Smoker Current or Past)
(9) 64.2%
Diabetes mellitus (10) 71.4%
Hypertension (11) 78.5%
Hyperlipidemia (6) 42.8%
Chronic Kidney Disease
(6) 42.8%
N = 14
Rutherford 4 (2) 14.2%
Rutherford 5 (9) 64.2%
Rutherford 6 (3) 21.4%
Multilevel disease
(14) 100%
Aortoiliac (6) 42.8%
Femoropopliteal (12) 85.7%
Tibial (13) 92.8%
![Page 28: Directional Atherectomy and Anti- Restenotic Therapy in ......Carlos Abel Gutierrez Diaz I have the following potential conflicts of interest to report: X Consulting: Medtronic, Bard,](https://reader030.fdocuments.us/reader030/viewer/2022040803/5e3e6f4c9f9d867e060a74d5/html5/thumbnails/28.jpg)
N = 14
Technical success 13 (92.8%)
Occlusions/Stenosis
13 (92.8%)/1 (7.2%)
DCB Femoropopliteal/Tibial
12 (85.7%)/ 6 (42.8)
Stent (4) 28.5%
Dissection (2) 14.2%
Acute Arterial Thrombosis
(1) 7.1%
Distal Embolization
(1) 7.1%
N = 14
Arterial access complication
(1) 7.1%
Bleeding 0
Pseudoaneurysm 0
Amputation (1) 7.1%
Calcification (12) 85.7%
![Page 29: Directional Atherectomy and Anti- Restenotic Therapy in ......Carlos Abel Gutierrez Diaz I have the following potential conflicts of interest to report: X Consulting: Medtronic, Bard,](https://reader030.fdocuments.us/reader030/viewer/2022040803/5e3e6f4c9f9d867e060a74d5/html5/thumbnails/29.jpg)
Conclusions
• Complex lesions are determinants of poor outcome in endovascular surgery.
• Vessel preparation with DA before DCB is safe.
• Calcification and long lesions are potential predictors for superior outcome for DAART: multilevel disease?
• A RCT is needed to determine the benefits of DA + DCB.
![Page 30: Directional Atherectomy and Anti- Restenotic Therapy in ......Carlos Abel Gutierrez Diaz I have the following potential conflicts of interest to report: X Consulting: Medtronic, Bard,](https://reader030.fdocuments.us/reader030/viewer/2022040803/5e3e6f4c9f9d867e060a74d5/html5/thumbnails/30.jpg)
Directional Atherectomy and Anti-Restenotic Therapy in Multilevel Disease
Carlos Abel Gutierrez Diaz MD Mexico City
Angeles Mocel Hospital